Treatment of HER2-positive breast cancer: current status and future perspectives. (Q37962332)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124364%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Treatment of HER2-positive breast cancer: current status and future perspectives (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124364%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124364%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Luca Gianni

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124364%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

4

Edith A Perez

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124364%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Carlos L Arteaga

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124364%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Mark X Sliwkowski

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124364%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

C Kent Osborne

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124364%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

English

0 references

publication date

29 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124364%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124364%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124364%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

16-32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124364%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22124364%20AND%20SRC:MED&resulttype=core&format=json

The discovery of receptor tyrosine kinases: targets for cancer therapy

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Untangling the ErbB signalling network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Mechanism of action of trastuzumab and scientific update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Management of small HER2-positive breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Adjuvant targeted therapy in early breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Trastuzumab: A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Adjuvant trastuzumab in HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Treatment beyond progression: is it moving from belief to evidence?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (H

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Trastuzumab versus lapatinib: the cardiac side of the story

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Does lapatinib work against HER2-negative breast cancers?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

HER2 therapy: molecular mechanisms of trastuzumab resistance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Ertumaxomab: a trifunctional antibody for breast cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

The PI3K pathway as drug target in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

PI3K kinase and scaffold functions in heart.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

The role of HER2 in angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Integrating bevacizumab into the treatment of patients with early-stage breast cancer: focus on cardiac safety

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Jumping higher: is it still possible? The ALTTO trial challenge

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Figitumumab (CP-751,871) for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

The E75 HER2/neu peptide vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.177

Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial.

31 March 2020

1 reference

12 December 2020

Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials

1 reference

12 December 2020

Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells

1 reference

12 December 2020

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

1 reference

12 December 2020

Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer

1 reference

12 December 2020

Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions

1 reference

12 December 2020